Tachyphylaxis of intravenous immunoglobulin in refractory inflammatory myopathy

A. M. Reimold, M. E. Weinblatt

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


We describe 2 patients with refractory inflammatory myositis who had an initial favorable response to intravenous immunoglobulin (IVIG) therapy. In contrast to all other reported cases, our patients reached a nadir in creatine phosphokinase (CPK) levels at 6 and 14 weeks after initiation of therapy, respectively, then experienced a relentless rise in CPK levels as well as a return of muscle weakness while still receiving IVIG. While IVIG may benefit some patients with refractory myositis, future studies must address the sustained efficacy of this agent.

Original languageEnglish (US)
Pages (from-to)1144-1145
Number of pages2
JournalJournal of Rheumatology
Issue number6
StatePublished - Jan 1 1994


  • Dermatomyositis
  • Intravenous immunoglobulin
  • Myositis
  • Polymyositis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Tachyphylaxis of intravenous immunoglobulin in refractory inflammatory myopathy'. Together they form a unique fingerprint.

Cite this